Sodium and water retention in heart failure and diuretic therapy: Basic mechanisms

Cleveland Clinic Journal of Medicine

Volumn 73, Issue SUPPL.2, 2006, Pages

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54049093044     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.Suppl_2.S2     Document Type: Article

References (29)

1. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341:577-585.
2. Peters JP. The role of sodium in the production of edema. N Engl J Med 1948; 239:353-362.
3. Cadnapaphornchai MA, Gurevich AK, Weinberger HD, Schrier RW. Pathophysiology of sodium and water retention in heart failure. Cardiology 2001; 96:122-131.
4. Schrier RW. Pathogenesis of sodium and water retention in highoutput and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 1988; 319:1065-1072.
5. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006; 52:5-18.
6. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996; 30:229-249.
7. McLay JS, McMurray JJ, Bridges AB, Fraser CG, Struthers AD. Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. Am Heart J 1993; 126:879-886.
8. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985; 103:1-6.
9. Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol 1999; 10(Suppl 12):S258-S265.
10. Burns KD, Li N. The role of angiotensin II-stimulated renal tubular transport in hypertension. Curr Hypertens Rep 2003; 5:165-171.
11. Padia SH, Howell NL, Siragy HM, et al. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension 2006; 47:537-544.
12. Eiskjaer H, Bagger JP, Danielsen H, et al. Mechanisms of sodium retention in heart failure: relation to the renin-angiotensin-aldosterone system. Am J Physiol 1991; 260:F883-F889.
13. Schoolwerth A, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin-converting enzyme inhibitor therapy. A Statement for Healthcare Professionals From the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104:1985-1991.
14. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73:615-621.
15. DiBona GF, Herman PJ, Sawin LL. Neural control of renal function in edema-forming states. Am J Physiol 1988; 254:R1017-R1024.
16. Dupont AG. Effects of carvedilol on renal function. Eur J Clin Pharmacol 1990; 38(Suppl 2):S96-S100.
17. DiBona GF, Sawin LL. Effect of metoprolol administration on renal sodium handling in experimental congestive heart failure. Circulation 1999; 100:82-86.
18. Sica DA. Hyponatremia and heart failure-pathophysiology and implications. Congest Heart Fail 2005; 11:274-277.
19. Szatalowicz VL, Velazquez H, Chaimowitz C, et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981; 305:263-266.
20. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 1:1385-1390.
21. Funayama H, Nakamura T, Saito T, et al. Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int 2004; 66:1387-1392.
22. Goldsmith SR, Francis GS, Cowley AW Jr. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 1986; 58:295-299.
23. Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int 1984; 26:183-189.
24. Pretzlaff RK, Vardis RJ, Pollack MM. Aminophylline in the treatment of fluid overload. Crit Care Med 1999; 27:2782-2785.
25. Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003; 284:F11-F21.
26. Ellison DH, Velazquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest 1989; 83:113-126.
27. Sica DA. Metolazone and its role in edema management. Congest Heart Fail 2003; 9:100-105.
28. Murray MD, Haag KM, Black PK, Hall SD, Brater DC. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy 1997; 17:98-106.
29. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57:601-609.